Igrene (ABI) Q3 2025 earnings summary

Executive summary

• Operating loss for the quarter was -2,010 KSEK compared to -1,069 KSEK in the same quarter last year.

• The company focuses on extracting hydrogen and carbon from biogenic methane using a CO2-free process in partnership with SEID AS.

• Plans for a demonstration plant were hindered by regulatory challenges, with environmental permit applications denied and subsequent appeals rejected.

• The company continues to seek alternative locations for its demonstration facility and maintains its strategic direction.

Financial highlights

• No revenue was reported for the quarter or the same period last year.

• Operating expenses increased to 2,010 KSEK from 1,069 KSEK year-over-year.

• Net loss for the quarter was -2,010 KSEK, unchanged from operating loss.

• Cash and cash equivalents at quarter-end were 6,300 KSEK, up from 2,072 KSEK a year earlier.

• Equity at quarter-end was 24,405 KSEK, with a solid equity ratio of 95.2%.

Outlook and guidance

• The company will continue collaboration with SEID AS and seek new sites for the demonstration plant.

• Ongoing commitment to commercializing methane-to-hydrogen and carbon technology in Europe.